Steven W J Lamberts
Overview
Explore the profile of Steven W J Lamberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
4296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lamberts S, Hofland L
Eur J Endocrinol
. 2019 Aug;
181(5):R173-R183.
PMID: 31398712
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over...
2.
van den Beld A, Kaufman J, Zillikens M, Lamberts S, Egan J, van der Lely A
Lancet Diabetes Endocrinol
. 2018 Jul;
6(8):647-658.
PMID: 30017799
During ageing, the secretory patterns of the hormones produced by the hypothalamic-pituitary axis change, as does the sensitivity of the axis to negative feedback by end hormones. Additionally, glucose homoeostasis...
3.
Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Feelders R, Lamberts S, et al.
Oncotarget
. 2018 Mar;
9(19):14791-14802.
PMID: 29599907
Somatostatin receptors are a pivotal target for treatment of pancreatic neuroendocrine tumors (pNET), either with somatostatin analogues (SSA) or radiolabeled SSA. The highest affinity target for the most commonly used...
4.
Gatto F, Feelders R, Franck S, Van Koetsveld P, Dogan F, Kros J, et al.
J Clin Endocrinol Metab
. 2017 Mar;
102(6):2009-2018.
PMID: 28323931
Context: First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment...
5.
Pivonello R, Waaijers M, Kros J, Pivonello C, de Angelis C, Cozzolino A, et al.
Endocrine
. 2016 Oct;
57(2):314-325.
PMID: 27738887
The dopamine D receptor is the main dopamine receptor expressed in the human normal pituitary gland. The aim of the current study was to evaluate dopamine D receptor expression in...
6.
Oberg K, Lamberts S
Endocr Relat Cancer
. 2016 Oct;
23(12):R551-R566.
PMID: 27697899
Acromegaly is a hormonal disorder that arises when the pituitary gland secretes excess growth hormone (GH), which in turn stimulates a concomitant increase in serum insulin-like growth factor 1 (IGF-1)...
7.
Gatto F, Biermasz N, Feelders R, Kros J, Dogan F, van der Lely A, et al.
Eur J Endocrinol
. 2016 Feb;
174(5):651-62.
PMID: 26888629
Objective: The high expression of somatostatin receptor subtype 2 (SSTR2 also known as sst2) usually present in growth hormone (GH)-secreting adenomas is the rationale for therapy with somatostatin analogs (SSAs)...
8.
van Adrichem R, de Herder W, Kamp K, Brugts M, de Krijger R, Sprij-Mooij D, et al.
Neuroendocrinology
. 2016 Feb;
103(6):815-25.
PMID: 26836610
Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) express insulin-like growth factor (IGF)-related factors [IGF1, IGF2; insulin receptor (IR)-A, IR-B; IGF-binding protein (IGFBP) 1-3] as well as somatostatin (SSTRs) and dopamine D2 receptors...
9.
De Martino M, Van Koetsveld P, Feelders R, Lamberts S, de Herder W, Colao A, et al.
Endocrine
. 2015 Dec;
52(3):664-7.
PMID: 26645813
No abstract available.
10.
Creemers S, Hofland L, Lamberts S, Feelders R
Expert Opin Pharmacother
. 2015 Jul;
16(12):1829-44.
PMID: 26133755
Introduction: Endogenous Cushing's syndrome (CS) is characterized by chronic overproduction of cortisol and is associated with increased mortality and morbidity. It can be caused by a pituitary adenoma, ectopic adrenocorticotropic...